Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.

By Javier Fernández, M. Navasa, R. Planas, S. Montoliu, D. Monfort, G. Soriano, C. Vila, A. Pardo, E. Quintero, V. Vargas and 3 more. Gastroenterology, 2007

648 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/96088932a5b913fb02b3800a09a842278a4b0ed6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. P. Ginés
2. G. Garcia‐Tsao
3. M. Bernardi
4. W. Laleman
5. P. Angeli
6. J. Trebicka
7. Aleksander Krag
8. A. Sanyal

In Hepatology

1. P. Ginés
2. M. Bernardi
3. P. Angeli
4. G. Garcia‐Tsao
5. W. Laleman
6. J. Trebicka
7. B. Runyon
8. Rajeshwar P. Mookerjee

In Infectious Diseases

1. J. Vila

Citations in the corpus

• Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012 (2013, background): “2, BUN 25 or serum Na 130) or liver failure (Child score 9 and bilirubin 3.(150,154,156,159,160,161) More liberal use of these antibiotics would be predicted to lead to colonization with, and subsequent infection by, resistant flora.”
• EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. (2018, methodology): “2 mg/dl, blood urea nitrogen level ≥25 mg/dl, or serum sodium level ≤130 mEq/L) to receive norfloxacin (400 mg/day for 12 months) or placebo [276].”
• Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study (2012, neutral): “Other multiresistant bacteria — 1 (10) 1 (6) 2 (7) NS Other infectionsk (n/%) 1 (2) 2 (4) 12 (25) 15 (10.”
• Acute-on chronic liver failure. (2012, background): “Administration of prophylactic norfloxacin, a selective gut decontaminant reduced the incidence of renal failure and improved survival [102].”
• Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. (2014, background): “62%) [154].”